News

Filter

Current filters:

Cardio-vascularXarelto

1 to 9 of 87 results

Bayer's Xarelto gets label update in Europe

Bayer's Xarelto gets label update in Europe

20-01-2015

German drug major Bayer has updated the label for its Xarelto (rivaroxaban) in Europe.

BayerCardio-vascularGermanyPharmaceuticalRegulationXarelto

UK’s NICE backs another use for Bayer’s Xarelto

UK’s NICE backs another use for Bayer’s Xarelto

23-10-2014

In draft guidance published today for consultation, the UK’s health costs watchdog the National Institute…

BayerCardio-vascularPharmaceuticalPricingRegulationUKXarelto

Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

Benefit for once-daily Xarelto in the first trial to evaluate prospective use in AF patients undergoing cardioversion

02-09-2014

German pharma and chemical major Bayer has released results from the X-VeRT* study, demonstrating that…

BayerCardio-vascularPharmaceuticalResearchXarelto

New studies planned to further expand indications for Xarelto

New studies planned to further expand indications for Xarelto

29-08-2014

German pharma major Bayer and partner Janssen Research & Development, a unit of US health care giant…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalResearchXarelto

Acute coronary syndrome treatment market to more than triple by 2023

Acute coronary syndrome treatment market to more than triple by 2023

30-07-2014

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary…

Acute coronary syndromealirocumabAmgenBayerCardio-vascularEuropeevolocumabJapanMarkets & MarketingMerck & CoPfizerPharmaceuticalSanofiUSAXareltoZontivity

Brazil and Mexico physicians’ preferences on anticoagulants

25-07-2014

Novel oral anticoagulants (NOACs) such as Bayer’s Xarelto (rivaroxaban), Boehringer Ingelheim’s Pradaxa…

BayerBoehringer IngelheimBrazilBristol-Myers SquibbCardio-vascularEliquisMarkets & MarketingMexicoPfizerPharmaceuticalPradaxaPricingXarelto

High price of novel antithrombotics a major deterrent to patient access in China

High price of novel antithrombotics a major deterrent to patient access in China

10-06-2014

The high cost of therapy remains a significant barrier for uptake of novel oral anticoagulants (NOACs)…

BayerBoehringer IngelheimBristol-Myers SquibbCardio-vascularChinaEliquisMarkets & MarketingPharmaceuticalPradaxaPricingWarfarin SodiumXarelto

1 to 9 of 87 results

COMPANY SPOTLIGHT

Menarini

Back to top